Core Viewpoint - Hengda Group Holdings (03616) announced a capital injection agreement involving its subsidiary, Xuchang Hengda, and Xuchang City Investment, which will increase the registered capital of Xuchang Hengrun from RMB 100 million to RMB 160 million [1] Group 1: Capital Injection Details - Xuchang Hengda will inject RMB 24 million into Xuchang Hengrun [1] - Xuchang City Investment will inject RMB 36 million into Xuchang Hengrun [1] - Post-injection, Hengda's equity in Xuchang Hengrun will be diluted from 80% to 65%, while Xuchang City Investment's equity will increase from 20% to 35% [1] Group 2: Board's Perspective - The board, including independent non-executive directors, believes the terms of the capital injection are fair and reasonable, aligning with the overall interests of the company and its shareholders [1] - No directors have significant interests in the capital injection, and no directors are required to abstain from voting on the related board resolution [1]
恒达集团控股(03616)：许昌恒达拟注入许昌市恒润注册资本2400万元